Cowen & Co. Reaffirms Their Buy Rating on NuVasive

By Ryan Adsit

Cowen & Co. analyst Josh Jennings reiterated a Buy rating on NuVasive (NASDAQ: NUVA) on October 9 and set a price target of $83. The company’s shares closed yesterday at $50.58, close to its 52-week low of $50.34.

According to, Jennings is a 2-star analyst with an average return of 0.0% and a 53.3% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Corindus Vascular Robotics, Boston Scientific Corp, and Zimmer Biomet Holdings.

Currently, the analyst consensus on NuVasive is Strong Buy and the average price target is $79.64, representing a 57.5% upside.

In a report issued on September 28, Piper Jaffray also reiterated a Buy rating on the stock with a $90 price target.

The company has a one-year high of $81.68 and a one-year low of $50.34. Currently, NuVasive has an average volume of 1.28M.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NUVA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. is medical device company, which engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V.